This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
by Zacks Equity Research
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
by Zacks Equity Research
Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.
How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 288%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 288.1% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
bluebird's (BLUE) Gene Therapy Gets FDA Nod for Beta-Thalassemia
by Zacks Equity Research
bluebird's (BLUE) Zynteglo gets FDA-approval for transfusion-dependent beta-thalassemia in adult and pediatric patients. The stock gains.
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study
by Zacks Equity Research
Artelo Biosciences (ARTL) reports positive pre-clinical data from one of its FABP5 inhibitors in anxiety-related disorders. Stock up.
Wall Street Analysts Think Sutro Biopharma, Inc. (STRO) Could Surge 295%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 294.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 25.68% and 105.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
by Zacks Equity Research
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration
by Zacks Equity Research
Sutro Biopharma (STRO) inks a partnership and licensing deal with Astellas Pharma to discover and develop iADCs for cancer patients not responding to existing therapies.
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -6.33% and 48.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -55% and 11.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Sutro Biopharma (STRO) This Earnings Season?
by Zacks Equity Research
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma, Inc. (STRO) Moves 6.4% Higher: Will This Strength Last?
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Implied Volatility Surging for Sutro Biopharma (STRO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Sutro Biopharma (STRO) stock based on the movements in the options market lately.
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 0.00% and -3.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro (STRO) Ovarian Cancer Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
Sutro's (STRO) investigational antibody-drug conjugate therapy, STRO-002, gets Fast Track designation from the FDA for advanced ovarian cancer.
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 69.05% and 103.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Sutro Biopharma, Inc. (STRO) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sutro Biopharma, Inc. (STRO) Surges 6.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 29.51% and 111.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -164.29% and -32.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
by Zacks Equity Research
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.